Jefferies Downgrades XOMA, Ltd. (XOMA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Ladenburg Thalmann Downgrades XOMA, Ltd. (XOMA) to Neutral
July 22, 2015 2:32 PM EDTLadenburg Thalmann downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Neutral with a price target of $1.00 (from $6.00).
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $4.40 yesterday.
... MoreRBC Capital Downgrades XOMA, Ltd. (XOMA) to Sector Perform
July 22, 2015 1:38 PM EDTRBC Capital downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Sector Perform with a price target of $2.00 (from $8.00).
Analyst Adnan Butt said, "Phase III Behcets study was higher risk but going forward is likely to create uncertainty around Phase III... More
Cowen Downgrades XOMA, Ltd. (XOMA) to Market Perform
July 22, 2015 12:57 PM EDTCowen downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Market Perform after the company announced that gevo's EYEGUARD-B trial in Behçets uveitis did not meet its primary endpoint. The firm said the gevo's viability is now in question.
Analsyt Phil Nadeau... More
It's NOT 'Game Over' for XOMA (XOMA), Wedbush Says; PT to $13
July 22, 2015 12:55 PM EDTWedbush analyst Liana Moussatos cut here price target on XOMA, Ltd. (NASDAQ: XOMA) to $13.00 (from $17.00) after Gevokizumab failed to meet the primary endpoint in its Phase 3 EYEGUARDB trial in patients with Behçets disease uveitis (BDU). However, the firm maintained its Outperform rating saying it is... More
Unusual 11 Mid-Day Movers 7/22: (SLTD) (LPCN) (BZUN) Higher; (XOMA) (ANGI) (CZR) Lower
July 22, 2015 12:51 PM EDTXOMA (Nasdaq: XOMA) 74.3% LOWER; announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.
Solar3D, Inc. (Nasdaq: SLTD) 24.4% HIGHER; announced preliminary results for the second quarter ended June 30, 2015. Revenue for the 2015 second quarter is expected to exceed $11.0 million. This represents an increase... More
Piper Jaffray Downgrades XOMA, Ltd. (XOMA) to Neutral
July 22, 2015 11:11 AM EDTPiper Jaffray downgraded XOMA, Ltd. (NASDAQ: XOMA) from Overweight to Neutral.
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $4.40 yesterday.
... MoreXOMA (XOMA) Announced Phase 3 EYEGUARD-B Missed Primary Objective
July 22, 2015 8:01 AM EDTXOMA (NASDAQ: XOMA) announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.
"Although the study did not achieve its main objective, we did see signals of drug activity such as preserved visual acuity, less severe ocular exacerbations... More
